Enanta Pharmaceuticals logo

Enanta PharmaceuticalsNASDAQ: ENTA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 March 2013

Next earnings report:

20 November 2024

Last dividends:

N/A

Next dividends:

N/A
$232.02 M
-88%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-68%vs. 3y high
51%vs. sector
-84%vs. 3y high
48%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:02:49 GMT
$10.95-$0.29(-2.62%)

Dividend

No data over the past 3 years
$17.97 M$17.93 M
$17.97 M-$22.66 M

Analysts recommendations

Institutional Ownership

ENTA Latest News

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
zacks.com02 October 2024 Sentiment: POSITIVE

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
businesswire.com26 September 2024 Sentiment: POSITIVE

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV.

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
zacks.com05 August 2024 Sentiment: POSITIVE

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.

Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
zacks.com15 July 2024 Sentiment: NEUTRAL

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research06 May 2024 Sentiment: POSITIVE

Enanta Pharmaceuticals (ENTA) reported a quarterly loss of $1.47 per share, which was higher than the Zacks Consensus Estimate of a loss of $1.26 per share. This is an improvement from the loss of $1.79 per share reported in the same quarter last year.

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
Seeking Alpha07 February 2024 Sentiment: POSITIVE

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research07 February 2024 Sentiment: NEGATIVE

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.

Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
Zacks Investment Research05 January 2024 Sentiment: POSITIVE

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

5 Secret Santa Stocks to Pop Surprise Returns
Zacks Investment Research19 December 2023 Sentiment: POSITIVE

Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.

How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%
Zacks Investment Research27 November 2023 Sentiment: POSITIVE

The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What type of business is Enanta Pharmaceuticals?

Enanta Pharmaceuticals, Inc. is an American biotechnology company specializing in the development of small molecule drugs for viral infections and liver diseases. The company was founded in 2004 and is headquartered in Hayward, California, USA. Enanta Pharmaceuticals is conducting clinical development in the following areas: RSV (respiratory syncytial virus). RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia in children under one year of age in the United States. NASH (non-alcoholic steatohepatitis). HBV (hepatitis B virus) - a potentially life-threatening liver infection.

What sector is Enanta Pharmaceuticals in?

Enanta Pharmaceuticals is in the Healthcare sector

What industry is Enanta Pharmaceuticals in?

Enanta Pharmaceuticals is in the Biotechnology industry

What country is Enanta Pharmaceuticals from?

Enanta Pharmaceuticals is headquartered in United States

When did Enanta Pharmaceuticals go public?

Enanta Pharmaceuticals initial public offering (IPO) was on 21 March 2013

What is Enanta Pharmaceuticals website?

https://www.enanta.com

Is Enanta Pharmaceuticals in the S&P 500?

No, Enanta Pharmaceuticals is not included in the S&P 500 index

Is Enanta Pharmaceuticals in the NASDAQ 100?

No, Enanta Pharmaceuticals is not included in the NASDAQ 100 index

Is Enanta Pharmaceuticals in the Dow Jones?

No, Enanta Pharmaceuticals is not included in the Dow Jones index

When was Enanta Pharmaceuticals the previous earnings report?

No data

When does Enanta Pharmaceuticals earnings report?

The next expected earnings date for Enanta Pharmaceuticals is 20 November 2024